Innoviva EBITDA Margin 2012-2026 | INVA
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Innoviva (INVA) over the last 10 years. The current EBITDA margin for Innoviva as of March 31, 2026 is .
| Innoviva EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2026-03-31 | $0.40B | $0.21B | 51.90% |
| 2025-09-30 | $0.39B | $0.21B | 53.98% |
| 2025-06-30 | $0.37B | $0.22B | 59.03% |
| 2025-03-31 | $0.37B | $0.23B | 60.65% |
| 2024-12-31 | $0.36B | $0.21B | 58.22% |
| 2024-09-30 | $0.35B | $0.20B | 57.51% |
| 2024-06-30 | $0.33B | $0.18B | 53.64% |
| 2024-03-31 | $0.31B | $0.15B | 47.91% |
| 2023-12-31 | $0.31B | $0.15B | 48.71% |
| 2023-09-30 | $0.29B | $0.13B | 45.86% |
| 2023-06-30 | $0.29B | $0.40B | 138.62% |
| 2023-03-31 | $0.32B | $0.45B | 142.59% |
| 2022-12-31 | $0.33B | $0.50B | 149.85% |
| 2022-09-30 | $0.37B | $0.58B | 154.42% |
| 2022-06-30 | $0.40B | $0.38B | 93.81% |
| 2022-03-31 | $0.40B | $0.39B | 99.24% |
| 2021-12-31 | $0.39B | $0.40B | 101.02% |
| 2021-09-30 | $0.38B | $0.38B | 100.53% |
| 2021-06-30 | $0.37B | $0.37B | 100.27% |
| 2021-03-31 | $0.34B | $0.35B | 100.58% |
| 2020-12-31 | $0.34B | $0.34B | 101.48% |
| 2020-09-30 | $0.32B | $0.33B | 102.48% |
| 2020-06-30 | $0.30B | $0.31B | 102.00% |
| 2020-03-31 | $0.29B | $0.29B | 101.40% |
| 2019-12-31 | $0.26B | $0.27B | 101.53% |
| 2019-09-30 | $0.27B | $0.27B | 101.13% |
| 2019-06-30 | $0.26B | $0.27B | 101.92% |
| 2019-03-31 | $0.26B | $0.27B | 102.27% |
| 2018-12-31 | $0.26B | $0.26B | 99.23% |
| 2018-09-30 | $0.25B | $0.25B | 99.20% |
| 2018-06-30 | $0.24B | $0.23B | 97.06% |
| 2018-03-31 | $0.23B | $0.22B | 93.48% |
| 2017-12-31 | $0.22B | $0.20B | 92.66% |
| 2017-09-30 | $0.19B | $0.17B | 89.58% |
| 2017-06-30 | $0.18B | $0.16B | 90.34% |
| 2017-03-31 | $0.15B | $0.14B | 91.95% |
| 2016-12-31 | $0.13B | $0.13B | 94.74% |
| 2016-09-30 | $0.11B | $0.11B | 93.75% |
| 2016-06-30 | $0.09B | $0.09B | 92.47% |
| 2016-03-31 | $0.07B | $0.07B | 91.67% |
| 2015-12-31 | $0.06B | $0.05B | 89.09% |
| 2015-09-30 | $0.04B | $0.03B | 84.62% |
| 2015-06-30 | $0.03B | $0.02B | 57.69% |
| 2015-03-31 | $0.02B | $0.00B | -6.25% |
| 2014-12-31 | $0.01B | $-0.02B | -212.50% |
| 2014-09-30 | $0.00B | $0.00B | 0.00% |
| 2014-06-30 | $0.00B | $0.00B | -100.00% |
| 2014-03-31 | $0.00B | 0 | 0.00% |
| 2013-12-31 | $0.00B | $-0.02B | -666.67% |
| 2013-09-30 | $0.01B | $-0.07B | -875.00% |
| 2013-06-30 | $0.01B | $-0.10B | -1055.56% |
| 2013-03-31 | $0.01B | $-0.12B | -1377.78% |
| 2012-12-31 | $0.14B | $-0.01B | -3.70% |
| 2012-09-30 | $0.13B | $-0.01B | -7.46% |
| 2012-06-30 | $0.14B | $-0.01B | -4.32% |
| 2012-03-31 | $0.14B | $0.01B | 4.17% |
| 2011-12-31 | $0.02B | $-0.10B | -443.48% |
| 2011-09-30 | $0.03B | $-0.09B | -340.00% |
| 2011-06-30 | $0.02B | $-0.08B | -316.67% |
| 2011-03-31 | $0.02B | $-0.07B | -300.00% |
| 2010-12-31 | $0.02B | $-0.07B | -300.00% |
| 2010-09-30 | $0.02B | $-0.08B | -357.14% |
| 2010-06-30 | $0.02B | $-0.08B | -350.00% |
| 2010-03-31 | $0.02B | $-0.08B | -376.19% |
| 2009-12-31 | $0.03B | $-0.08B | -304.00% |
| 2009-09-30 | $0.03B | $-0.07B | -262.96% |
| 2009-06-30 | $0.03B | $-0.07B | -259.26% |
| 2009-03-31 | $0.03B | $-0.07B | -264.29% |
| 2008-12-31 | $0.02B | $-0.09B | -354.17% |
| 2008-09-30 | $0.02B | $-0.10B | -429.17% |
| 2008-06-30 | $0.02B | $-0.12B | -491.67% |
| 2008-03-31 | $0.02B | $-0.14B | -613.04% |
| 2007-12-31 | $0.02B | $-0.16B | -745.45% |
| 2007-09-30 | $0.02B | $-0.17B | -819.05% |
| 2007-06-30 | $0.02B | $-0.18B | -852.38% |
| 2007-03-31 | $0.02B | $-0.18B | -838.10% |
| 2006-12-31 | $0.02B | $-0.18B | -880.00% |
| 2006-09-30 | $0.02B | $-0.18B | -994.44% |
| 2006-06-30 | $0.02B | $-0.18B | -1173.33% |
| 2006-03-31 | $0.01B | $-0.16B | -1261.54% |
| 2005-12-31 | $0.01B | $-0.15B | -1208.33% |
| 2005-09-30 | $0.01B | $-0.13B | -1100.00% |
| 2005-06-30 | $0.01B | $-0.12B | -966.67% |
| 2005-03-31 | $0.01B | $-0.11B | -1036.36% |
| 2004-12-31 | $0.01B | $-0.10B | -1133.33% |
| 2004-09-30 | $0.01B | $-0.09B | -1271.43% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.760B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |